
|Articles|September 22, 2015
Jenna Earl
Author(s)Jenna Earl
Advertisement
Jenna Ealr is Senior Consultant at Blue Latitude
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
5




